Metabolic Solutions Development Company’s focus is the discovery of novel molecular targets and development of new therapeutics to treat metabolic diseases associated with mitochondrial dysfunction.
Our scientists have identified a new mitochondrial protein complex located at the crossroads of metabolism, called mTOT. This breakthrough understanding into the mechanism of action of insulin sensitization has led to the development of novel insulin sensitizers shown in human clinical trials to have the potential to produce durable anti-diabetic effects.
Capitalizing on unique insights into metabolism, MSDC has developed two novel insulin sensitizers, MSDC-0160 and MSDC-0602. These mTOT modulators, MSDC-0160 and MSDC-0602, have been shown to effectively lower glucose without the same degree of unwanted and often unacceptable side effects experienced with current insulin sensitizers, including fluid retention, weight gain, heart failure, edema, and bone loss. In addition, these investigational new drugs have been shown in clinical and preclinical studies to have the potential to treat polycystic kidney disease and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
The company’s discoveries cap more than a decade of research conducted by MSDC scientists and others to develop a more effective oral insulin sensitizer. For the first time since the last approval of an insulin sensitizer in 1999, researchers have new evidence into how a class of drugs like insulin sensitizers can effectively treat metabolic dysfunction while minimizing off-target effects.